B-Cell-Depleting Immune Therapies as Potential New Treatment Options for Systemic Sclerosis
Background: Systemic sclerosis (SSc), also known as scleroderma, is a complex, chronic autoimmune disease characterized by fibrosis of the skin and internal organs, vasculopathy, and immune system dysregulation. The treatment of SSc has historically focused on symptom management and slowing down dis...
Saved in:
| Main Authors: | Gerhard Zugmaier, Matthias Klinger, Marion Subklewe, Faraz Zaman, Franco Locatelli |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Sclerosis |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2813-3064/3/1/5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Elevated Fab glycosylation of autoantibodies maintained during B cell depletion therapy
by: Anika M. Valk, et al.
Published: (2025-04-01) -
Blinatumomab in pediatric B-acute lymphoblastic leukemia
by: Yifang Cheng, et al.
Published: (2025-07-01) -
Persistent B Cell Depletion After Rituximab for Autoimmune and Glomerular Diseases: A Case Series
by: Orhan Efe, et al.
Published: (2025-05-01) -
BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA
by: Ugo Testa, et al.
Published: (2024-08-01) -
Alterations in peripheral blood immune cell profiles of neuromyelitis optica spectrum disorder across different phases and after B cell depletion therapy
by: Xuying Wang, et al.
Published: (2025-06-01)